External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different

PD‐L1 inhibitors are part of first line treatment options for patients with advanced non‐small cell lung cancer. PD‐L1 immunohistochemistry (IHC) assays act as either a companion or a complementary diagnostic. The purpose of this study is to describe the experience of external quality assurance (EQA...

Descripción completa

Detalles Bibliográficos
Autores principales: Dodson, Andrew, Parry, Suzanne, Lissenberg‐Witte, Birgit, Haragan, Alex, Allen, David, O'Grady, Anthony, McClean, Emma, Hughes, Jamie, Miller, Keith, Thunnissen, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164369/
https://www.ncbi.nlm.nih.gov/pubmed/31849189
http://dx.doi.org/10.1002/cjp2.153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164369/
https://www.ncbi.nlm.nih.gov/pubmed/31849189
http://dx.doi.org/10.1002/cjp2.153

Ejemplares similares